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doi:10.1Objective: Although consensus in cardiac surgery supports tight control of perioperative hyperglycemia (glucose
<120 mg/dL), recent studies in critical care suggest moderate glycemic control may be superior. We sought to
determine whether tight control or moderate glycemic control is optimal after coronary artery bypass grafting.
Methods: From 1995 to 2008, a total of 4658 patients with known diabetes or perioperative hyperglycemia
(preoperative glycosylated hemoglobin 8 or postoperative serum glucose>126 mg/dL) underwent isolated
coronary artery bypass grafting at our institution. Patients were stratified into 3 postoperative glycemic groups:
tight (126 mg/dL), moderate (127–179 mg/dL), and liberal (180 mg/dL). Preoperative risk factors, glycemic
management, and postoperative outcomes were analyzed.
Results:Operative mortality was 2.5% (119/4658); major complication rate was 12.5% (581/4658). Relative to
moderate group, more patients in tight group had preoperative renal failure (tight 16.4%, 22/134, moderate
8.3%, 232/2785, P ¼ .001) and underwent emergent operations (tight 5.2%, 7/134, moderate 1.9%, 52/
2785, P ¼ .007); however, Society of Thoracic Surgeons predicted mortality risk was lower in tight group
(P<.001). Moderate group had lowest mortality (tight 2.9%, 4/134, moderate 2.0%, 56/2785, liberal 3.4%,
59/1739, P¼ .02) and incidence of major complications (tight 19.4%, 26/134, moderate 11.1%, 308/2785, lib-
erate 14.2%, 247/1739, P<.001). Risk-adjusted major complication incidence (adjusted odds ratio 0.7, 95%
confidence interval 0.58–0.87) and mortality (adjusted odds ratio 0.6, 95% confidence interval 0.37–0.83)
were lower with moderate glucose control than with tight or liberal management.
Conclusions: Moderate glycemic control was superior to tight glycemic control, with decreased mortality
and major complications, and may be ideal for patients undergoing isolated coronary artery bypass grafting.
(J Thorac Cardiovasc Surg 2011;141:543-51)Diabetes mellitus is a well-documented risk factor for cor-
onary artery disease and is common among patients who
undergo coronary revascularization. In addition to patients
with known diabetes, many patients acquire perioperative
insulin resistance and stress-induced hyperglycemia after
coronary artery bypass grafting (CABG) procedures.1 Post-
operative glycemic control in critically ill patients after gen-
eral and cardiovascular surgical procedures has become
a debated issue among trained intensivists.2-4 Data in thee Division of Thoracic and Cardiovascular Surgery,a Department of Surgery,
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Mpast have suggested that tight control of postoperative
serum glucose after cardiac surgery is the optimal
approach, and tight control has therefore become the
classically accepted treatment paradigm.5,6
Several previous studies have evaluated hyperglycemia
in critically ill patients, including those undergoing cardiac
surgery. In a landmark randomized trial, Van den Berghe
and colleagues7 reported a 3%mortality benefit with inten-
sive insulin therapy (target serum glucose, 80–110 mg/dL)
relative to conventional treatment (target serum glucose,
180–200 mg/dL).7 Similarly, the Portland Diabetic Project,
a nonrandomized, prospective protocol, has demonstrated
that tight perioperative glycemic control with continuous
insulin infusion, relative to sliding-scale intermittent subcu-
taneous insulin, is safe in reducing serum glucose to nearly
euglycemic levels, with decreased mortality, lessened infec-
tion, and shorter stay after open cardiac procedures.8-10
Collectively, these studies have led to the accepted tight
control strategy for postoperative glucose management
after cardiac surgery.
In contrast, recent reports in critical care that included
cardiac surgical patients have suggested that tight glucose
control (80–110 mg/dL) in the intensive care unit (ICU)
results in worse mortality than standard control (180
mg/dL).2,11,12 Although The Society of Critical Care ofrdiovascular Surgery c Volume 141, Number 2 543
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MMedicine supports close glucose monitoring in the intensive
setting, specific definitions for the ideal strategy have not
been clarified as of the most recent consensus statement
(June 2009).13 A recent meta-analysis of 29 randomized tri-
als reported no significant difference in mortality when
stratified by glucose goal (very tight 110 mg/dL vs mod-
erately tight<150 mg/dL) or intensive care setting in surgi-
cal, medical, and mixed medical and surgical patients.14
These authors concluded that tight glucose control was
associated with decreased septicemia but significantly in-
creased risk of hypoglycemia.14
To further support these new findings, the NICE-SUGAR
(Normoglycemia in Intensive Care Evaluation—Survival
Using Glucose Algorithm Regulation) trial demonstrated
a 2.8% mortality benefit with standard control relative to
tight control in medical and surgical patients, including
those in cardiovascular ICUs.15 Importantly, 3 contempo-
rary prospective trials2,16,17 in medical and combined
medical–surgical intensive care patients were unable to
replicate the initial report by Van den Berghe.
Taken together, these conflicting results suggest that the
optimal management of postoperative serum glucose levels
in patients after cardiac surgery remains debatable. In light
of recent findings advocating moderate glucose control in
critically ill patients,15,18 we performed a retrospective
review at our institution to delineate more clearly an ideal
strategy for postoperative glucose management after
isolated coronary revascularization.MATERIALS AND METHODS
Data Source
Institutional data stripped of patient identifiers from 1995 through 2008
were obtained from the University of Virginia Health System Clinical Data
Repository (CDR). The CDR is maintained by the Division of Clinical
Informatics, Department of Public Health Sciences, and contains patient
information managed through the University of Virginia Health System.
The CDR collects data and links the cardiac surgical–related information
at our institution on the basis of variables defined by the Society of Tho-
racic Surgeons (STS) national database.19 All variables analyzed represent
STS definitions. Cases with data missing completely at random were not
excluded from analysis; however, variables with large missing data under-
went casewise deletion. Approval for this investigation, including patient
consent waiver, was obtained by the human investigation committee at
the University of Virginia (HSR 14832).544 The Journal of Thoracic and Cardiovascular SurgPatient Selection
We identified 8662 patients who underwent isolated CABG during this
study period at our institution. Patients were selected if they had known di-
abetes mellitus or preoperative glycosylated hemoglobin of at least 8, or if
they had evidence of perioperative hyperglycemia, either (1) immediate
postoperative serum glucose level greater than 126 mg/dL or (2) 3-day
postoperative average serum glucose level greater than 126 mg/dL. Patient
selection criteria were developed to capture patients with diabetes, poorly
controlled or undiagnosed diabetes mellitus, and stress-induced insulin
resistance. The perioperative period was defined from the day of surgery
through 3 days after the procedure, because as this period has been shown
to be critical for glycemic control after cardiac surgery.20,21
Glycemic Control Groups
Patients were stratified into 3 arbitrary postoperative glycemic groups,
which were adapted from the World Health Organization guidelines22
and based on 3-day average postoperative serum glucose levels. The tight
group was composed of those patients with average serum glucose not
more than 126 mg/dL, the moderate group was composed of patients
with average serum glucose levels of 126.1 to 179.9 mg/dL, and the liberal
group was composed of patients with average serum glucose of at least
180 mg/dL.
Serum glucose levels reported through the CDR reflected point-of-care
testing. Glucose levels for each postoperative day were not tabulated, and
as such the average glucose level reported reflects the cumulative aggregate
of all available reported serum glucose measurements of patients receiving
insulin therapy, irrespective of location in the hospital. Glucose measure-
ments were performed at least every 2 hours by protocol. The postoperative
average data reflect all measurements collected after the patient’s arrival in
the thoracic and cardiovascular ICU through 72 hours after ICU admission.
Hypoglycemia was defined as any reported serum glucose level of 60
mg/dL or less. Symptoms (tachycardia, diaphoresis, anxiety, and so on)
were not included to identify hypoglycemic events, because patients in
this study were frequently receiving b-blockade, intravenous inotropic
support, or sedation, and also could be mechanically ventilated. Thus the
intrinsic catecholamine-mediated physiologic response to hypoglycemia
is potentially masked in the ICU setting.Statistical Analysis
Primary outcomes of interest were mortality and major complication
rate. A major complication was defined to include permanent stroke, renal
failure as defined by the STS, prolonged ventilation (>24 hours), deep
sternal wound infection, or reoperation for any reason.
The strength of association for each variable was measured with appro-
priate statistical hypothesis testing. The statistical significance of differ-
ences in proportions for categoric variables was evaluated by the Pearson
c2 or Fisher’s Exact test where appropriate. The statistical significance
of differences in mean values for continuous variables was assessed with
single-factor analysis of variance models. Results for the total series of hy-
pothesis tests conducted in the study population were corrected for multiple
comparison bias by adjusting each probability by the false discovery rate.
Data are shown as numbers and percentages by group or as mean  SD,
except where indicated otherwise.
Separate multivariable logistic regression models were developed to
calculate the adjusted odds of mortality and major complication rate. Vari-
ables for the models were selected a priori on the basis of the established
literature to control for differences in patient demographic characteristics,
risk factors, operative features, and type of postoperative glucose manage-
ment strategy. The liberal group was used for comparative reference, be-
cause a glucose level greater than 180 mg/dL has been well documented
to be detrimental and the tight control group was not an appropriate refer-
ence because of its small size. The 95% confidence intervals for all cova-
riates in the models were calculated. The models’ predictive capacity toery c February 2011
Bhamidipati et al Perioperative Managementdiscriminate was measured with the area under the receiver–operator char-
acteristic curve. The Hosmer–Lemeshow c2 test for goodness-of-fit was
performed to assess differences in model calibration for deciles of model
probabilities. Relative magnitude of the calculated Wald statistic was
used to determine the contribution of each covariate to the regression
model. Adjusted odds ratios are presented for each covariate, along with
their 95% confidence intervals. All data were analyzed with the Statistical
Package for the Social Sciences 17 software (SPSS Inc, an IBM Company,
Chicago, Ill).
RESULTS
Perioperative Glucose Management
A total of 4658 patients were identified, including 4433
(95.2%) who underwent primary CABG and 225 (4.8%)
who underwent reoperative CABG. Average perioperative
glucose level was stratified according to postoperative glu-
cose group (Figure 1). Serum glucose averages ranged be-
tween 118.9 mg/dL and 214.6 mg/dL. Despite 25 patients
(0.5%) with preoperative (day of surgery) serum glucose
measurements of 60 mg/dL or less, there were only 16 pa-
tients (0.3%) whose first postoperative serum glucose level
was in the hypoglycemic range. There were 2 patients in the
tight group (1.5%) who had preoperative serum glucose
levels of 60 mg/dL or less on the day of surgery. Interest-
ingly, mean initial preoperative glucose level was incremen-
tally higher in the tight control group (133.7 mg/dL) than in
the moderate control group (124.5 mg/dL). Postoperatively,
a hypoglycemic reading on the first serum glucose level was
proportionally most common in the tight control group
(tight 1.5%, 2/132, moderate 0.4%, 12/2773, and liberal
0.1%, 2/1737, P ¼ .02).
Risk Factors and Operative Features of Patients
Undergoing Isolated CABG
Preoperative risk factors and operative features of pa-
tients were analyzed by postoperative serum glucose level
(tight, moderate, or liberal). There were notable differences
between glucose groups (Table 1). The tight group (3-day
postoperative serum glucose average, 126 mg/dL) had
the greatest proportion of patients with known diabetes,FIGURE 1. Perioperative glucose management by group. Data shown
reflect mean  SEM of serum glucose levels.
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Mwhereas the moderate group (3-day postoperative serum
glucose average, 126.1–179.9 mg/dL) had the fewest. Pre-
operative renal failure was lowest in the liberal control
group and highest in the tight control group (P¼ .001). Ste-
roid use was most common in the tight control group
(P<.001). The tight group also had the greatest proportion
of patients in New York Heart Association functional class
IV congestive heart failure relative to the other groups
(P < .001). Liberal group patients were more likely to
have undergone an elective operation (P<.001), whereas
those in the tight group were more likely to have undergone
an urgent operation (P< .001) or an emergent operation
(P ¼ .003). The moderate group had minimally different
yet statistically shorter crossclamp time (P ¼ .05) and per-
fusion time (P< .001) than did the other groups. Despite
these clinical differences, the STS predicted mortality risk
for the tight group was lower than that for the moderate
group (tight 0.2%  1.1%, moderate 0.9%  1.9%,
P<.001).
Outcomes After Isolated CABG Stratified by
Postoperative Glucose Level
In contrast to their preoperative glucose level on the day
of surgery, the first postoperative glucose level was lowest
in the tight control group (tight 115.2  29.3 mg/dL, mod-
erate 126.2  41.5 mg/dL, and liberal group 178.3  65.6
mg/dL, P< .001). The incidences of postoperative stroke
and deep sternal wound infection were similar across
groups (Table 2). Sepsis, prolonged ventilation, postopera-
tive renal failure, and the need for new dialysis were highest
in the tight glucose group. Relative to patients in the tight
control group, those in the moderate control group on aver-
age had a 2-day shorter postoperative stay (P ¼ .001).
Importantly, major complication rate and mortality were
lowest in the moderate glucose group (Figure 2).
Independent Predictors of Mortality
Multivariable regression identified age, female sex, pre-
operative renal failure, left ventricular ejection fraction,
and previous coronary revascularization as highly predic-
tive of mortality (area under the curve, 0.84). Importantly,
even when controlling for the significant differences be-
tween groups, the risk-adjusted odds of mortality were re-
duced by 40% with moderate control relative to liberal
management (Table 3). Tight glucose control did not inde-
pendently influence mortality.
Independent Predictors of Major Complication Rate
Similar to mortality, multivariable regression identified
age, female sex, preoperative renal failure, left ventricular
ejection fraction, and previous coronary revascularization
as predictors of major complications (area under the curve,
0.76). In addition, nonelective surgery was also highly pre-
dictive of major complications. Importantly, although tightrdiovascular Surgery c Volume 141, Number 2 545
TABLE 1. Risk factors and operative features by glucose management group
Variables Tight (n ¼ 134) Moderate (n ¼ 2785) Liberal (n ¼ 1739) P value
Preoperative
Patient age (y, mean  SD) 64.4  11.4 64.2  10.6 63.7  9.9 .19
Sex (no.)
Female 44 (32.8%) 661 (23.7%) 488 (28.1%) .001
Male 90 (67.2%) 2124 (76.3%) 1251 (71.9%) .001
Risk factor (no.)
Stroke 6 (4.5%) 419 (15.0%) 266 (15.3%) .93
Peripheral arterial disease 31 (23.1%) 462 (16.6%) 322 (18.5%) .06
Diabetes* 71 (52.9%) 929 (33.4%) 848 (48.7%)
Hypertension 110 (82.1%) 2038 (73.2%) 1231 (70.8%) .009
Dialysis* 12 (8.9%) 48 (1.7%) 19 (1.1%)
Renal failure 22 (16.4%) 232 (8.3%) 127 (7.3%) .001
Atrial tachycardia or fibrillation 9 (6.7%) 193 (6.9%) 123 (7.1%) .98
Ventricular tachycardia or fibrillation 3 (2.2%) 68 (2.4%) 72 (4.1%) .005
Steroids* 8 (5.9%) 68 (2.4%) 45 (2.6%)
New York Heart Association functional class (no.)
I* 6 (4.5%) 312 (11.2%) 409 (23.5%)
II* 26 (19.4%) 550 (19.8%) 696 (40.0%)
III* 46 (34.3%) 961 (34.5%) 384 (22.1%)
IV* 56 (41.8%) 962 (34.5%) 250 (14.4%)
Day of surgery serum glucose
(mg/dL, mean  SD)*
129.4  40.5 124.7  53.6 147.5  69.9
Operative
Operative status (no.)
Elective* 58 (43.3%) 1416 (50.8%) 1071 (61.6%)
Urgent* 69 (51.5%) 1307 (46.9%) 609 (35.0%)
Emergency 7 (5.2%) 52 (1.9%) 55 (3.2%) .003
Left ventricular ejection fraction (%, mean  SD)* 49.4%  13.1% 50.8%  12.5% 47.5%  11.3%
Crossclamp time (min, mean  SD) 74.2  33.5 67.6  33.4 69.1  35.3 .05
Perfusion time (min, mean  SD)* 95.4  37.9 91.5  41.9 99.7  44.8
STS predicted risk mortality (%, mean  SD)* 0.2%  1.1% 0.9%  1.9% 2.3%  3.2%
Tight, 126 mg/dL; moderate, 127–179 mg/dL; liberal, 180 mg/dL; STS, Society of Thoracic Surgeons. *P<.001.
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Mglucose control did not independently influence major com-
plications, the risk-adjusted odds of major complications
were reduced by 30% with moderate control relative to
liberal goals (Table 4).
DISCUSSION
This study was designed to evaluate our institutional per-
formance and identify the optimal glucose management
strategy after isolated coronary revascularization. We found
major complications and 30-day mortality to be lowest
among patients with moderate glycemic control. Moreover,
moderate postoperative glycemic control was indepen-
dently associated with a lower incidence of major complica-
tions than was tight control and was independently
associated with improved survival relative to liberal control.
We used the liberal control group as our reference because
poor outcomes after liberal glycemic goals are well docu-
mented and our tight control group was disproportionately
small. These findings corroborate recent data from other
specialties.2,3,14,23 Acute ischemic stroke and myocardial546 The Journal of Thoracic and Cardiovascular Surginfarction are both significantly increased among patients
who have stress-induced hyperglycemia, irrespective of
diabetes status.24-27 It is well known that patients with
diabetes have a lower mortality risk when admitted to the
hospital than do patients without diabetes who have
surges in glycemic index.1,6,28,29 Furthermore, our
findings are consistent with the recent review that
evaluated the importance of tight glucose control (80–110
mg/dL) in surgical patients, including postoperative
cardiac surgical patients, and concluded that a glucose
level of 140 to 180 mg/dL was associated with the best
risk–benefit ratio.11 In addition, a recent meta-analysis of
11,425 patients concluded that there was no evidence to
support the use of intensive insulin therapy in general
medical and surgical ICU patients.30
Several authors have evaluated the optimal perioperative
glucose management in critically ill patients, including
those undergoing cardiac operations.7,15,31 Postoperative
glucose management after cardiovascular procedures has
been extensively reviewed by the Portland Diabeticery c February 2011
TABLE 2. Postoperative outcomes by glucose management group
Variables Tight (n ¼ 134) Moderate (n ¼ 2785) Liberal (n ¼ 1739) P value
First postoperative glucose (mg/dL, mean  SD)* 115.2  29.3 126.2  41.5 178.3  65.6
Postoperative glucose (mg/dL, mean  SD)* 118.98  6.2 152.4  14.8 214.6  30.2
Complications (no.)
Permanent stroke 4 (2.9%) 35 (1.3%) 35 (2.0%) .06
Gastrointestinal event 1 (0.8%) 47 (1.7%) 43 (2.5%) .11
Deep sternal wound infection 2 (1.5%) 13 (0.5%) 10 (0.6%) .27
Multiorgan dysfunction 1 (0.8%) 30 (1.1%) 13 (0.8%) .52
Atrial fibrillation 28 (20.9%) 553 (19.9%) 366 (21.1%) .62
Sepsis 5 (3.7%) 27 (0.9%) 25 (1.4%) .01
Prolonged ventilation* 22 (16.4%) 166 (5.9%) 108 (6.2%)
Renal failure* 12 (8.9%) 97 (3.5%) 108 (6.2%)
Dialysis* 10 (7.5%) 29 (1.0%) 2 (0.1%)
Resource utilization (no.)
Ventilator (h, mean  SD) 38.8  171.1 19.8  134.9 32.5  95.0 .19
Intensive care unit (h, mean  SD) 86.7  178.7 53.4  164.6 63.6  162.6 .10
Postoperative stay (d, mean  SD)* 8.5  11.7 6.0  7.4 6.6  8.0
Primary outcomes
Major complications* 26 (19.4%) 308 (11.1%) 247 (14.2%)
Mortality 4 (2.9%) 56 (2.0%) 59 (3.4%) .02
Tight, 126 mg/dL; moderate, 127–179 mg/dL; liberal, 180 mg/dL. *P<.001.
TABLE 3. Multivariable regression for predictors of mortality
Adjusted odds 95% Confidence P
Bhamidipati et al Perioperative ManagementProject, which has advocated tight glucose control (70–120
mg/dL) with the use of continuous insulin therapy.
Important work by Lazar and colleagues32 has also been
cited in support of tight glycemic control after coronary re-
vascularization. Moreover, the STS Practice Guideline Se-
ries on Blood Glucose Management During Adult Cardiac
Surgery suggests that serum glucose levels should be main-
tained at or below 180 mg/dL to reduce mortality. Support-
ing these recommendations, our study found that patients
with 3-day postoperative average serum glucose levels
greater than 180 mg/dL had the highest mortality of any
group.
Contradictory findings from the randomized single-
center Belgian experience reported by Van den Berghe7
and the multicontinent NICE-SUGAR trial,15 both of whichFIGURE 2. Major complications and mortality by group. Data shown re-
flect percentage of major complications and mortality by serum glucose
levels.
The Journal of Thoracic and Caincluded patients in cardiovascular ICUs, have led to further
confusion of the optimal glucose strategy. Despite their
groundbreaking contribution, Van den Berghe and col-
leagues have drawn criticism for an underpowered design
with unique patient characteristics, intensive care enteral
feeding protocols, and timing of insulin therapy.33,34
Three recent prospective trials that included surgical
patients failed to replicate findings from the initial study
by Van den Berghe supporting tight glucose control,
including one (nonsurgical patients) by Van den Berghe’s
own group.2,16,17Covariates ratio interval value
Patient age (y) 1.1 1.03–1.07 <.001
Female sex 2.4 1.62–3.62 <.001
Stroke 1.9 1.09–3.35 .02
Diabetes 0.9 0.62–1.44 .79
Renal failure 7.1 4.64–10.78 <.001
Heart failure 1.4 0.87–2.12 .17
Preoperative steroid use 1.8 0.83–4.02 .14
Left ventricular
ejection fraction (%)
0.9 0.95–0.98 <.001
Previous coronary
artery bypass operation
2.4 1.27–4.47 .007
Previous valve operation 3.8 0.67–21.13 .13
Nonelective status 1.5 1.00–2.25 .05
Glucose control*
Tight 0.5 0.17–1.51 .22
Moderate 0.6 0.37–0.83 .004
*Reference is liberal glucose control.
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TABLE 4. Multivariable regression for predictors of major
complications
Covariates
Adjusted odds
ratio
95% Confidence
interval
P
value
Patient age (y) 1.0 1.01–1.03 <.001
Female sex 1.5 1.24–1.88 <.001
Stroke 1.2 0.86–1.74 .25
Diabetes 1.2 1.00–1.51 .04
Renal failure 10.1 7.90–12.89 <.001
Heart failure 1.5 1.16–1.86 .001
Preoperative steroid use 0.9 0.49–1.50 .59
Left ventricular
ejection fraction (%)
0.9 0.98–0.99 <.001
Previous coronary
artery bypass operation
1.7 1.12–2.48 .01
Previous valve operation 0.6 0.11–3.40 .56
Nonelective status 1.6 1.31–1.94 <.001
Glucose control*
Tight 1.0 0.60–1.70 .97
Moderate 0.7 0.58–0.87 .001
*Reference is liberal glucose control.
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MSeveral studies have attempted to address this dichotomy of
strict versus less strict postoperative glucose control, and 2
treatment dogmas have evolved. The first is that of tight post-
operative glycemic control (upper threshold of 120 mg/dL),
and the second is that of normoglycemic or moderate
glycemic control (upper threshold of 200 mg/dL).6,28,32,35,36
Our study supports maintaining levels between 126 and
180 mg/dL, because our highest mortality was seen in the
liberal management group. We did not demonstrate
superior results with tight glycemic control, and we therefore
question whether this is necessary in light of the risks of
hypoglycemia.
The importance of glucose variance cannot be under-
stated. In a recent retrospective report by Hermanides and
coworkers37 on surgical ICU patients, serum glucose vari-
ance when combined with high serum glucose levels was
associated with the highest mortality. Often, the greatest
challenge is ensuring consistent postoperative glycemic
control. Unfortunately, in this study we were unable to as-
sess the degree of glucose variance, because data were col-
lected by the repository as a cumulative average of glucose
measurements.
In addition, we use point-of-care assessment, results of
which have been known to differ from arterial blood gas–
derived serum glucose levels by as much as 10%. As
such, the initial approval of glucometers by the Food and
Drug Administration, with a known and accepted variance
of 15%, was intended for optimizing outpatient and ambu-
latory glycemic management, and not for determining rig-
orous intensive care. Finally, according to the current
literature there may be differences as great as 20% between
point-of-care testing and reference laboratory values of
serum glucose levels.548 The Journal of Thoracic and Cardiovascular SurgDuring the course of this study, as at most institutions,
our insulin protocols have evolved. From 1995 to 1999,
our primary method of treating postoperative hyperglyce-
mia in the cardiovascular ICU was physician directed and
guided by attending cardiovascular surgeons according to
the best practices at the time. From 1999 to 2005, we adap-
ted the Portland Diabetic Project for glucose management
for our postoperative cardiovascular patients.5 Routinely,
the average of serum glucose measurements taken every
2 hours per 24 hour period was used to follow postoperative
trends. From 2005 to 2008, glycemic management contin-
ued to evolve to a point at which hourly measurements
were collected for trending and treatment for patients
receiving an insulin infusion, with at least 18 glucose mea-
surements for patients not receiving an infusion. Subse-
quent data interpretation led to the recent (2009) protocol
change at our institution, so that now patients (irrespective
of unit or operative status) are managed with a more relaxed
postoperative glucose goal (180 mg/dL).
There are several limitations to note. Because this is a ret-
rospective analysis, an inherent bias limits our ability to an-
alyze variables outside of the STS database. The dissimilar
patient cohorts sorted by glucose thresholds diminish pro-
spective inference. The use of mean perioperative serum
glucose measures prevents commenting on the influences
on outcomes of disease chronicity, outpatient management
profile, and short-term fluctuations in glycemic manage-
ment. In addition, our sample size is not large enough to
stratify patients according to known diabetes and perioper-
ative hyperglycemia to answer the optimal glucose control
question. Importantly, as stated previously, we attempted
to identify all patients with known (including poorly
controlled) or undiagnosed diabetes mellitus and stress-
induced insulin resistance. Furthermore, we included
diabetes and glucose control strategy in our multivariate
analysis. Our results were derived from analyzing a hetero-
geneous cohort of patients across multiple years and are
influenced by the temporal bias in patient care, protocol de-
velopment, and newer medications. Specifically, our analy-
sis is a comparison of treatment strategies. Our 3 groups are
numerically unmatched, potentially representing variability
in the reported serum glucose levels, with differing risk pro-
files. As such, our analysis is unable to reflect on variations
in preoperative individual glycemic management and the
resultant influences in results. Nevertheless, we have at-
tempted to account for these differences by using regression
modeling.
CONCLUSIONS
In this retrospective analysis, our data support recent ran-
domized trials indicating that moderate control of hypergly-
cemia is not inferior to tight control in critically ill patients.
Importantly, we have failed to establish the superiority of
tight postoperative glycemic control, and we thereforeery c February 2011
Bhamidipati et al Perioperative Managementquestion the necessity of this threshold. In fact, moderate
control in this study was independently associated with
lower mortality and major complications among patients
after isolated coronary revascularization. On the basis of
our findings, we believe that moderate glycemic control
(150 mg/dL  15%) may be superior to tight control
(126 mg/dL) and entails few hypoglycemic events. Fur-
ther randomized prospective studies evaluating the optimal
postoperative glycemic regimen are necessary.
We thank Kenneth W. Scully and Judy G. Smith for their assis-
tance with data collection and editorial perspective.P
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Dr Anthony P. Furnary (Portland, Ore). Dr Ailawadi, since I
have to make this short, I really can’t make it sweet. I thought your
title was very clever, but the simple statistical fact is that neither
the title nor the conclusions are supported in any way by the
data presented, nor is it possible that any difference between tightrdiovascular Surgery c Volume 141, Number 2 549
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Mand moderate control, if it did actually exist, could have ever been
statistically detected in this study.
Let me explain. There are 134 patients in the tight group and
2700 in the moderate group. Because of the lack of a sufficient
number of patients in the tight group, the study was markedly un-
derpowered to detect any differences between the tight and mod-
erate groups. Power analysis reveals that the estimated power of
this study to detect a 1% absolute reduction in mortality between
these 2 groups was only 3%, nowhere near the 80% power sought
to ensure a valid finding. A quick c2 analysis comparing your mor-
tality data between these 2 groups shows a P value of .6. Even if
there had been no deaths at all in the tight group, the P value would
have still been insignificant at .1.
Furthermore, your study is based entirely on retrospective data
abstracted from an administrative—read ‘‘billing’’—database. Not
a clinical database, not an STS database, an administrative data-
base. Clinical outcomes from these databases are ‘‘assumed’’ by
interpreting coding information that is applied to patient charts
by hospital coders after discharge. Then, rather than using estab-
lished STS predicted risk scores, which you had, for logistic risk
adjustment, a new regression model was created.
What you have shown is that moderate control is superior to
no control at all, and this is a finding that is supported by 15
years of published literature on the subject. Moderate control
reduced mortality by 40% relative to no control. Interestingly,
the point estimate for tight control shows a 50% reduction in
mortality relative to the no control group. Again, however,
there weren’t enough patients to bring that point estimate to
statistical significance; even had there been no deaths at all
in the tight control group, it wouldn’t have made it into the
equation. To take those results and imply that moderate control
is superior to tight control when they weren’t even directly
compared, simply because it didn’t make it into the equation
because of the low number of patients, is either wishful think-
ing or misleading marketing rhetoric that is not supported by
your statistical data.
I have similar concerns about your morbidity statistics and con-
clusions. I don’t have time to go into them here. In addition, how-
ever, of the 5 major complications that you have analyzed, 3 of
them—stroke, prolonged ventilation, and reoperation—have never
ever been shown to be associated with, let alone caused by, hyper-
glycemia in cardiac surgical patients. Thus the treatment studied,
glycemic control, is unrelated to the complications examined. It
would be like looking at the effect of antibiotics on atrial fibrilla-
tion rate.
We all know our first responsibility is to our patients, and we all
come to this meeting looking for a sound bite, something we can
take home, something that we can implement in our practice. It
just worries me that the conclusion that you present, that moderate
control is ‘‘superior’’ to tight control, is a dangerous message to let
out, because the simple fact is that it is not supported by your data.
I have 3 questions. First, you cite moderate control articles from
the medical ICU literature that don’t include patients undergoing
CABG. Why should we as cardiac surgeons ignore both random-
ized and observational cardiac-specific trials totaling more than
36,000 patients that tell us that the optimal target for patients un-
dergoing CABG is in the range of 80 to 130 mg/dL in deference to
your 134 mg/dL tight glycemic control patients?550 The Journal of Thoracic and Cardiovascular SurgDr Ailawadi. Thank you for your comments. Getting back to
the comment about our use of a clinical data repository, these
data were merged with our STS database. We did use our STS
data, not purely administrative data. We actually merged the
data sets. So we believe that this actually provides better data
and more complete data, because the STS, as you know, does
not include many of these things that we are examining.
With the comment about stroke having never been associated
with glucose strategy, there was a randomized trial of 400 patients
by Gandhi published a couple of years ago comparing tight glu-
cose control with a more liberal or a more moderate glucose con-
trol, similarly to our study. It was a randomized study, and they did
find a worse stroke rate in patients with tight control. I realize that
it is not a perfect study, but that has been shown before.
In terms of the question about medical intensive care unit, if you
actually look at the NICE-SUGAR trial, although the article does
not specify the number of patients who underwent cardiac surgery,
it did include both medical and surgical patients. If you actually
look, some of the centers included were cardiovascular ICUs.
Dr Furnary. I am going to respond really quickly. First, there
were no patients undergoing CABG in that trial, or at least cer-
tainly fewer than 100. Second, the Gandhi trial only studied intra-
operative glycemic control, and the postoperative control was the
same between groups. It was a very bad study.
My next question, and I think I know your answer to this, is in
light of the serious statistical issues I have raised—and they are se-
rious—would you consider restating your conclusion and retitling
your article? Because you actually compared moderate control
with no control, not moderate to tight.
Dr Ailawadi. The moderate control was not compared with no
control; it was a more liberal control. It was essentially what was
being done for many years until data became available.
Dr Furnary. Right, so it is moderate versus liberal.
Dr Ailawadi. It was a physician-directed protocol that many
believe was the best at the time.
Dr Furnary.Would you agree that your study does not compare
moderate versus tight control?
Dr Ailawadi. I would agree that our reference group is the lib-
eral control group, not the tight control group, because the latter
cannot be a reference group with only 134 patients.
Dr Furnary. So you compared moderate control with your ref-
erence group but not moderate control with tight control?
DrAilawadi.And we compared tight control with the reference
group as well.
Dr Furnary. Thank you. So, finally, last question. With tight
control in Portland, our 3-day blood glucose average is 115 mg/
dL and our diabetes-associated CABG mortality in the last 10
years among more than 2000 such patients is 0.9%, with an STS
observed to expected ratio of 0.25, a quarter of the national average
mortality. So why do you think that the STS-derived observed to
expected ratios contained within your data, but not explicitly pre-
sented, of 13.6 for tight control, 2.3 for moderate, and 1.45 for no
control, were all significantly greater than 1?
Dr Ailawadi. Well, there are many potential reasons. Obvi-
ously, we are in a different situation, being at a training center,
than you are at your institution. And although I cannot address
that as the sole reason, an overall CABG mortality of roughly
2% is pretty similar to what the literature shows and what theery c February 2011
Bhamidipati et al Perioperative ManagementSTS shows. I know that there has been an issue to try to get it down
to 1%, and perhaps this will help us to do that, but I do believe that
tight control may not be necessary.
I would want to emphasize that glucose control is a necessary
thing. The question is, how tight do we really need to be? And if
there are worse mortalities and higher complications with a tight
strategy, then these findings of our study will be borne out in future
randomized studies. So this is not the be-all and end-all; I agree
with that. I think that this is an interesting study. We were a bit
surprised to see the findings, and I think it should lead to better
questioning in the future.
Dr Furnary. Thanks. I am sorry to rain on your parade. I think
there is another rainmaker over there.
Dr Harold L. Lazar (Boston, Mass). I just need to disclose that
we do have research support from the Eli Lilly Company but own
no stock in the company.
When I heard that Dr Furnary was going to discuss this presen-
tation, I didn’t think that I would have too much more to question
or add, but I would like to ask a couple of questions. When we
wrote the guidelines for the STS a couple of years ago, we stated
that the optimal glucose range would be between 120 to 180 mg/
dL, and we did so not really to endorse tight versus moderate
but to make it easier for people to have at least some compliance.
Subsequently, our own group has done a study in which we looked
at moderate versus aggressive control in a prospective randomized
fashion, comparing 90 to 120 mg/dL versus 120 to 180 mg/dL.
And what we found was that the tighter control group had better
control of inflammatory factors such as free fatty acids, but in re-
ality when we looked at the clinical end points and all the major
adverse cardiac and cerebrovascular events, there was absolutely
no difference.
So my first question to you is, why do you think that tight gly-
cemic control was detrimental? We have seen that it may not add
anymore—at least in the short term, we can’t comment on the long
term—but why should it be bad? And in answering this question, I
would like to ask you to focus on these points.What was the lowest
glucose level that was reached? Did you actually have a formal
protocol that actually titrated the glucose to achieve a certain
level? And how often did you measure glucose, and what did
you do when you reached the level that was lower, let’s say, than
80 mg/dL?
Dr Ailawadi. Excellent questions. So the first question is, why
dowe think this is bad? And, again, we don’t have data on the num-
ber of hypoglycemic events, but that is certainly a concern. There
has been a fair amount of literature on the effects of neuroglycope-
nia, and, many patients in our population were still in the ICU,
some of them still intubated. Those are difficult to assess, at least
clinically, and merely can be measured with a glucose measure-
ment.The Journal of Thoracic and CaIn terms of the lowest glucose level reached, we had patients
whose serum mean glucose levels were basically were as low as
about 85 to 90 mg/dL.
Did we have a formal protocol? Before 1999, it was a physi-
cian-directed protocol. It was not a protocol enforced by the insti-
tution. From 1999, on we adopted the Portland protocol, which has
since been modified as STS guidelines have improved, and we
follow the STS guidelines quite carefully.
Dr Robert Scott Kramer (Portland, Me).We need to interpret
the evidence supporting tight glycemic control with regard to the
context where execution of the protocol at the bedside is the key
to success. Well-trained and well-supervised bedside nurses can
make a significant difference in the safety of a tight glycemic con-
trol program. Some nurses canmanage an algorithm-driven insulin
drip with the skill of a pilot keeping an airplane flying straight and
level. I suspect that the NICE-SUGAR trial may have had some
problems with the execution of the protocol at the bedside, because
its hypoglycemia rate was so high. The lesson fromNICE-SUGAR
is that hypoglycemia is dangerous. Drs Furnary and Van den
Berghe and others have taught us that a tight glycemic control pro-
tocol executed well at the bedside improves outcomes.
Dr Ailawadi. I believe that we have taken glucose control very
seriously at the University of Virginia since the Portland diabetic
project was first published. We have a number of people who are
very interested in this, endocrinologists, nursing staff, and admin-
istrators, and our university is taking a very aggressive system-
wide hospital approach. So I do believe that we feel very strongly
that this is an important thing that we have undertaken.
Finally, in response to the question about how often we mea-
sure, in the past it had been a minimum of 12 measurements during
a 24-hour period. That has now increased to a minimum of 18mea-
surements during a 24-hour period.
Dr Lazar. I am anxious to add just a follow-up to that. I think
that the lack of a proper controlled regimen and not following these
patients on an hourly basis and making adjustments may be con-
tributory to some of the effects, because that is where people
who have noted problems with tight glycemic control in surgical
patients have gotten into trouble.
I guess my second question is, as we know, tight glycemic con-
trol is not only important in the first 24 hours but is important after
the first 24 hours and before the patient goes home. So what pro-
tocols did you have in effect to look at the effect of glycemic con-
trol once the patient has left the ICU?
Dr Ailawadi. Essentially our strategy is when patients are re-
ceiving insulin infusions, we do get hourly blood glucose levels.
When patients get out of the ICU from postoperative day 1 to 3,
they are transitioned gradually to a sliding scale and the insulin
infusion is turned off. This is all by protocol.rdiovascular Surgery c Volume 141, Number 2 551
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